Clinicopathological characteristics and outcomes of 23 patients with secretory carcinoma of major salivary glands

Abstract

This retrospective study investigated the clinicopathological characteristics of secretory carcinoma of salivary glands (SCSG) in 23 patients with histopathologically confirmed SCSG between January 2010 and December 2020. In total, 13 males and 10 females (ratio, 1.3:1) aged 10 − 69 years (median, 45 years) were enrolled in this study; the average disease duration was 2.44 years (0.25–20 years). Twenty-one patients (91.3%) had SCSG in the parotid gland, and two (8.7%) in the submandibular gland. All patients had single nodules of diameters 0.8–4.8 cm (average 2.6 cm); five with lymph node metastases, and two with distant metastases. Immunohistochemically, tumors stained positive for S-100, mammaglobin, CK7, GATA3 and pan-Trk, and negative for DOG1, P63, and calponin, with Ki-67 positivity from 1 to 50%. ETV6 gene rearrangement was confirmed in 15 patients. All patients underwent oncological resection, four had radioactive particles implanted postoperatively, one received chemotherapy, and seven underwent chemoradiotherapy. Six patients had regional recurrences, two distant metastases, and one died before the last follow-up. SCSGs are typically indolent, with a low locoregional recurrence rate and excellent survival. Prognosis is correlated to clinical stage, pathological grade, and surgical procedures.

Evaluation of the Clinical Utility of Genomic Profiling to Inform Selection of Clinical Trial Therapy in Salivary Gland Cancer

“…The success of NTRK-targeted therapies in patients with secretory carcinoma harbouring NTRK gene fusions represents a significant step forward for genetic based approaches in SGC. These patients were not represented in our cohort, possibly due to the lower frequency of recurrence in this subtype in comparison to other salivary gland cancer types [ 70 ].…”

Diagnostic accuracy of pan‐TRK immunohistochemistry in differentiating secretory carcinoma from acinic cell carcinoma of salivary gland—A systematic review

“…In this phase, 2 case reports 23,24 were excluded and finally, 13 articles were included for quantitative synthesis (Figure 1). 7,8,[12][13][14][15][16][17][18][19][20][21][22] 3.1 | Methodological characteristics of the studies Data extracted from all 13 studies including details on the country of origin, authors, total number, and histopathological type of SGTs and pattern of pan-TRK IHC manifestation are provided in Tables S1 & 1.…”

“…The included studies were conducted between 2017 and 2022, in more than 5 different countries: 4 in the USA, 7,12-14 2 in France, 16,18 3 in Japan, 8,15,21 2 in China 19,20 1 in Taiwan, 22 and 1 was multicentric. 17 A total of 623 different SGTs including 255 SCs and 82 AciCCs were identified.…”

Secretory carcinoma of the salivary gland: a multi‐institutional clinicopathologic study of 90 cases with emphasis on grading and prognostic factors

“…Moreover, due to the small cohorts included in previous studies, the risk of nodal metastasis, local recurrence, distant metastasis, and disease-related death ranged widely. The reported frequency of nodal metastasis ranged from 3% to 43%, 1,[15][16][17][18][19] local recurrence ranged from 3% to 38%, 1,15-20 distant metastasis ranged from 0% to 17%, 1,15,16,18,19,[21][22][23] and disease-related mortality ranged from 0% to 33%. 1,4,[16][17][18][19][20]22,24 Although these data indicated that SC generally behaves as a lowgrade salivary gland carcinoma, nodal metastasis, recurrence, and distant metastasis may occur in a small subset of cases.…”